利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

702 条记录 (耗时 0.034 秒)

    ALL-IN-ONE LUMINESCENCE-BASED POINT-OF-CARE TESTING DEVICE FOR VIRUS DIAGNOSIS
    1.
    发明公开
    ALL-IN-ONE LUMINESCENCE-BASED POINT-OF-CARE TESTING DEVICE FOR VIRUS DIAGNOSIS 审中-公开

    公开(公告)号：US20240287628A1

    公开(公告)日：2024-08-29

    申请号：US18173097

    申请日：2023-02-23

    申请人： The Hong Kong Polytechnic University

    发明人： Jianhua HAO ,  Menglin SONG ,  Man Chung WONG ,  Lihua LI

    IPC分类号： C12Q1/70 ,  C12Q1/6804 ,  C12Q1/6816

    CPC分类号： C12Q1/701 ,  C12Q1/6804 ,  C12Q1/6816 ,  G01N2333/005

    摘要： This invention provides an all-in-one device for virus diagnosis, especially for a target nucleic acid sequence or target antigens or anitbodies in a single sample, comprising: a sample chamber for holding a cuvette with a UCNP-based assay and said sample; a NIR light source; a sensor for measuring fluorescence emission from a UCNP-based assay comprising a light-to-frequency converter; Optics providing an optical path ensuring only fluorescence emission from said UCNP-based assay reaches said sensor; and a microcontroller; wherein said UCNP-based assay is a system comprising UCNP surface modified with a first oligo probe and AuNP surface modified with a second oligo probe, wherein said first oligo probe and said second oligo probe are independently complimentary to separate segments on said target nucleic acid sequence that are nearby each other; or/and a system comprising ligand-free UCNP with electrostatic attraction to said target protein and AuNR surface modified with antibodies for said target protein.

    Spectacle lens
    3.
    发明授权
    Spectacle lens 有权

    公开(公告)号：US12019312B2

    公开(公告)日：2024-06-25

    申请号：US18216013

    申请日：2023-06-29

    申请人： HOYA LENS THAILAND LTD. ,  THE HONG KONG POLYTECHNIC UNIVERSITY

    发明人： Chi Ho To ,  Siu Yin Lam ,  Takashi Hatanaka ,  Yasutake Masuda

    IPC分类号： G02C7/06

    CPC分类号： G02C7/06 ,  G02C2202/24

    摘要： A spectacle lens can inhibit ametropia of the eyes and ensure full visibility. The spectacle lens comprises: first refraction areas and second refraction areas. Each first refraction area has a first refraction force that may be based on a prescription for correcting the ametropia of the eyes. Each second refraction area has a refraction force different from the first refraction force and may function to focus images on the positions except the retina of the eyes, to inhibit the development of the ametropia. Near the central part of the lens, the second refraction areas form a plurality of independent island-shaped areas, and the first refraction areas form the areas beyond the areas of the second refraction areas.

    BECLIN 1-TARGETED STAPLED PEPTIDE AND PHARMACEUTICAL COMPOSITION
    4.
    发明公开
    BECLIN 1-TARGETED STAPLED PEPTIDE AND PHARMACEUTICAL COMPOSITION 审中-公开

    公开(公告)号：US20240190920A1

    公开(公告)日：2024-06-13

    申请号：US18550862

    申请日：2022-05-11

    申请人： Shenzhen Research Institute of the Hong Kong Polytechnic University ,  FUDAN UNIVERSITY

    发明人： Yanxiang ZHAO ,  Xianxiu QIU ,  Xiaozhe ZHANG ,  Na LI ,  Renxiao WANG

    IPC分类号： C07K7/08

    CPC分类号： C07K7/08

    摘要： A Beclin 1-targeting stapled peptide and a pharmaceutical composition. The stapled peptide includes an amino acid sequence at least 66.7% identical to amino acid residues 191-205 of Beclin 1, an amino acid residue E195 and an amino acid residue N202 in the stapled peptide are connected by a hydrocarbon staple to stabilize the α-helical structure of the stapled peptide. The hydrocarbon staple is located at a position in the stapled peptide closer to the Beclin1 coiled coil domain-stapled peptide binding interface, which can enhance the binding affinity of the stapled peptide to Beclin 1 by 10-30 fold. Compared to other autophagy inducers like rapamycin and Tat-Beclin 1 peptide, the optimized stapled peptide shows the unique profile of not only inducing autophagy but also significantly enhancing the endolysosomal degradation of cell surface oncogenic receptors EGFR and HER2 in HER2-positive cancer cells.